Neuronetics' Revenue Surges 132% YoY, Positions as Neurohealth Leader with FDA Clearance for Adolescent TMS Therapy.
ByAinvest
Tuesday, Sep 2, 2025 3:55 am ET1min read
STIM--
Neuronetics, Inc. (NASDAQ:STIM) reported Q2 2025 revenue of $38.1 million, a 132% YoY increase, driven by Greenbrook integration and expansion to 95 clinics. The company is expanding its SPRAVATO program and gained FDA clearance for NeuroStar in adolescents, establishing it as a first-line therapy. Revenue for fiscal 2025 is projected between $149 million and $155 million, with positive cash flow from operations anticipated by Q4 2025. The business continues investing in growth and talent, navigating challenges in profitability and stock volatility.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet